Efficacy and safety of Shexiang Baoxin Pill for stable coronary artery disease: A systematic review and meta-analysis of 42 randomized controlled trials

• Egile Nagusiak: Jingjing Wei (Egilea), Teng Ma (Egilea), Cheng Zhou (Egilea), Pengle Hao (Egilea), Bin Li (Egilea), Xinlu Wang (Egilea), Rui Yu (Egilea), Mingjun Zhu (Egilea), Yongxia Wang (Egilea)
• Formatua: Liburua
• Argitaratua: Frontiers Media S.A., 2022-11-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Objective: Patients with stable coronary artery disease (SCAD) still have a higher risk of adverse cardiovascular events. Shexiang Baoxin Pill (SBP) is widely used as a complementary and alternative treatment for SCAD. This study aimed to further verify the therapeutic effect and safety of SBP on SC...